Tag: Cholangiocarcinoma

First receiving accelerated approval from the FDA in 2020 for certain bile duct cancers, the specialized targeted therapy Pemazyre prompts the question: **Who is the manufacturer of pemigatinib?** The answer is Incyte Corporation, a global biopharmaceutical company focusing on the discovery, development, and commercialization of proprietary therapeutics.

According to reports, medication mix-ups are a common safety concern, underscoring the importance of verifying pills before consumption. For those wondering **what is an I9 pill used for?**, the answer is not simple, as the imprint is associated with two completely different medications with distinct physical appearances, mechanisms of action, and uses.

In May 2024, the FDA announced the final withdrawal of approval for Truseltiq (infigratinib), a targeted therapy for bile duct cancer, just three years after its accelerated approval. This decision was voluntary on the part of the drug's manufacturer and provides a compelling case study on the risks inherent in the accelerated approval pathway.